Silence Therapeutics PLC Additional Listing (3542C)

TIDMSLN

RNS Number : 3542C

Silence Therapeutics PLC

12 April 2017

Additional listing

12 April 2017

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has issued and allotted 190,000 new ordinary shares of 5p each ("Ordinary Shares") following the exercise of share options under the Employee Share Scheme.

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 20 April 2017. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

The total number of shares in issue, following admission, will be 69,991,624. The Company holds no shares in Treasury.

Enquiries:

 
 Silence Therapeutics plc                Tel: +44 (0)20 
  Ali Mortazavi, Chief Executive          3457 6900 
  Officer 
  David Ellam, Chief Financial Officer 
 Canaccord Genuity Limited (Nominated    Tel: +44 (0)20 
  Adviser and Joint Broker)               7523 8350 
  Henry Fitzgerald-O'Connor/Emma 
  Gabriel 
 Peel Hunt LLP (Joint Broker)            Tel: +44 (0)20 
  James Steel/Oliver Jackson              7418 8900 
 Media Enquiries:                        Tel: +44 (0) 
  FTI Consulting                          20 3727 1000 
  Simon Conway/Brett Pollard/Stephanie 
  Cuthbert 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ALSGGURPCUPMGPP

(END) Dow Jones Newswires

April 12, 2017 08:30 ET (12:30 GMT)